Last reviewed · How we verify
NCT06999291
Ovarian Reserve in Intensive Care Patients
trial testing Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS) in Anti-Mullerian Hormone Deficiency in 75 participants. Not yet recruiting.
15 July 2025
Quick facts
| Lead sponsor | Haseki Training and Research Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 15 June 2025 |
| Primary completion | 15 July 2025 |
| Estimated completion | 15 November 2025 |
Drugs / interventions tested
- Glaskow coma scala, The Acute Physiology and Chronic Health Evaluation System- APACHE, Injury Severity Score- ISS)
Conditions studied
- Anti-Mullerian Hormone Deficiency — all drugs for Anti-Mullerian Hormone Deficiency →
Sponsor
Haseki Training and Research Hospital
Who can join
Adults 18 to 35, female only, with Anti-Mullerian Hormone Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gastrointestinal, pulmonary, nephrological, cardiac, neurologic and psychological effects in critically ill patients followed in the intensive care unit have been shown in the literature. However, the effects on ovarian reserve in these patients have not been sufficiently investigated and studies investigating this issue are limited in the literature. The synthesis, release frequency and amplitude of reproductive hormones change under stress. In addition, changes in ovarian homeostasis affect ovarian reserve. The aim of this study was to evaluate ovarian reserve in critically ill patients followed up in the intensive care unit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06999291
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anti-Mullerian Hormone Deficiency
Currently open trials in the same condition.
- NCT04381299 — Will Autologous Platelet Rich Plasma Able To Restore Ovarian Function? · active not recruiting
Other Haseki Training and Research Hospital trials
Trials by the same sponsor.
- NCT07502482 — The Effect of Magnesium on Post-spinal Headaches · not yet recruiting
- NCT07201181 — Maternal Smoking Exposure and Newborn Outcomes: Study Using Urinary Cotinine · not yet recruiting
- NCT07203716 — Preparing Kids for MRI Using VR · NA · not yet recruiting
- NCT07165743 — Evaluation of Fetal Bladder Emptying During the 11-14 Weeks' Ultrasound Examination as a Negative Predictive Marker for · active not recruiting
- NCT07179861 — Comparing Artificial Intelligence and Physicians: A Vignette-Based Study in Pediatric Clinical Decision-Making · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06999291 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haseki Training and Research Hospital
- Last refreshed: 31 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06999291.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing